About Ivantis
Ivantis is a company based in Irvine (United States) founded in 2007 was acquired by Alcon in November 2021. Ivantis has raised $166.23 million across 7 funding rounds from investors including Alcon, RA Capital and Merieux Equity Partners. The company has 132 employees as of December 31, 2022. Ivantis operates in a competitive market with competitors including Glaukos, Myra Vision, Sensimed, Transcend Medical and Avisi Technologies, among others.
- Headquarter Irvine, United States
- Employees 132 as on 31 Dec, 2022
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ivantis, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ivantis
Ivantis has successfully raised a total of $166.23M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $25 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ivantis
Ivantis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Alcon, RA Capital and Merieux Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pivate equity firm that focuses on investing in healthcare and nutrition companies
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Investments are made in life sciences firms across all stages.
|
Locked | Locked | Locked |
Investor details for Ivantis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ivantis
Investment portfolio details for Ivantis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ivantis
Detailed financials for Ivantis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ivantis Comparisons
Peer comparison for Ivantis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ivantis
Ivantis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Glaukos, Myra Vision, Sensimed, Transcend Medical and Avisi Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of implants to treat glaucoma
|
|
| Locked | Locked | Locked |
Nanotechnology-based devices for glaucoma treatment are developed.
|
|
| Locked | Locked | Locked |
A contact lens-based platform for glaucoma monitoring is offered.
|
|
| Locked | Locked | Locked |
Minimally invasive glaucoma stents are developed to enhance aqueous outflow.
|
|
| Locked | Locked | Locked |
Nano-materials for glaucoma treatment implants are developed.
|
Detailed competitors of Ivantis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ivantis
Complete news archive for Ivantis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ivantis
Ivantis was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Ivantis is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Ivantis is a funded company, having raised a total of $166.23M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Ivantis is 132.
Ivantis Inc. was founded in 2007 in Irvine, United States, focusing on medical devices for ophthalmology. Solutions for primary open-angle glaucoma are developed by the company, including an intracanalicular scaffold designed as an implantable device. High intraocular pressures in patients are addressed through this technology. Operations center on innovation in glaucoma treatment, with the domain ivantisinc.com serving as the primary online presence.
Ivantis's top competitors include Glaukos, Myra Vision and Avisi Technologies.
Ivantis has 11 investors. Key investors include Alcon, RA Capital, Merieux Equity Partners, NEA, and Delphi Ventures.